Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00402558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Simultaneous Pancreas-kidney Transplantation With Campath Protocol
- Conditions
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Dr. Claudia Bösmüller
- Target Recruit Count
- 30
- Registration Number
- NCT00316810
- Locations
- 🇦🇹
University Hospital Innsbruck, Innsbruck, Tyrol, Austria
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 56
- Registration Number
- NCT00275509
- Locations
- 🇺🇸
The Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2006-10-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 90
- Registration Number
- NCT00235781
- Locations
- 🇺🇸
Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Stem Cell Transplantation for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT00176839
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00133367
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 30
- Registration Number
- NCT00130754
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
- Conditions
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2007-12-28
- Target Recruit Count
- 15
- Registration Number
- NCT00040651
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
- Conditions
- First Posted Date
- 2002-06-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT00040482
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00038857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.